

HB3129



104TH GENERAL ASSEMBLY

State of Illinois

2025 and 2026

HB3129

Introduced 2/18/2025, by Rep. William E Hauter

SYNOPSIS AS INTRODUCED:

720 ILCS 570/208

from Ch. 56 1/2, par. 1208

720 ILCS 642/Act rep.

Amends the Illinois Controlled Substances Act. Adds mitragynine and 7-hydroxymitragynine as Schedule III controlled substances. Repeals the Kratom Control Act.

LRB104 08036 RLC 18082 b

A BILL FOR

1 AN ACT concerning criminal law.

2 **Be it enacted by the People of the State of Illinois,**
3 **represented in the General Assembly:**

4 Section 5. The Illinois Controlled Substances Act is
5 amended by changing Section 208 as follows:

6 (720 ILCS 570/208) (from Ch. 56 1/2, par. 1208)

7 Sec. 208. (a) The controlled substances listed in this
8 Section are included in Schedule III.

9 (b) Unless specifically excepted or unless listed in
10 another schedule, any material, compound, mixture, or
11 preparation which contains any quantity of the following
12 substances having a stimulant effect on the central nervous
13 system, including its salts, isomers (whether optical
14 position, or geometric), and salts of such isomers whenever
15 the existence of such salts, isomers, and salts of isomers is
16 possible within the specific chemical designation;

17 (1) Those compounds, mixtures, or preparations in
18 dosage unit form containing any stimulant substances
19 listed in Schedule II which compounds, mixtures, or
20 preparations were listed on August 25, 1971, as excepted
21 compounds under Title 21, Code of Federal Regulations,
22 Section 308.32, and any other drug of the quantitative
23 composition shown in that list for those drugs or which is

1 the same except that it contains a lesser quantity of
2 controlled substances;

3 (2) Benzphetamine;

4 (3) Chlorphentermine;

5 (4) Clortermine;

6 (5) Phendimetrazine.

7 (c) Unless specifically excepted or unless listed in
8 another schedule, any material, compound, mixture, or
9 preparation which contains any quantity of the following
10 substances having a potential for misuse associated with a
11 depressant effect on the central nervous system:

12 (1) Any compound, mixture, or preparation containing
13 amobarbital, secobarbital, pentobarbital or any salt
14 thereof and one or more other active medicinal ingredients
15 which are not listed in any schedule;

16 (2) Any suppository dosage form containing
17 amobarbital, secobarbital, pentobarbital or any salt of
18 any of these drugs and approved by the Federal Food and
19 Drug Administration for marketing only as a suppository;

20 (3) Any substance which contains any quantity of a
21 derivative of barbituric acid, or any salt thereof:

22 (3.1) Aprobarbital;

23 (3.2) Butabarbital (secbutabarbital);

24 (3.3) Butalbital;

25 (3.4) Butobarbital (butethal);

26 (4) Chlorhexadol;

- (5) Methylprylon;
- (6) Sulfondiethylmethane;
- (7) Sulfonethylmethane;
- (8) Sulfonmethane;
- (9) Lysergic acid;
- (10) Lysergic acid amide;
- (10.1) Tiletamine or zolazepam or both, or any salt of either of them.

Some trade or other names for a tiletamine-zolazepam combination product: Telazol.

Some trade or other names for Tiletamine:

2-(ethylamino)-2-(2-thienyl)-cyclohexanone.

Some trade or other names for zolazepam:

4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e], [1,4]-diazepin-7(1H)-one, and flupyrazapon.

(11) Any material, compound, mixture or preparation containing not more than 12.5 milligrams of pentazocine or any of its salts, per 325 milligrams of aspirin;

(12) Any material, compound, mixture or preparation containing not more than 12.5 milligrams of pentazocine or any of its salts, per 325 milligrams of acetaminophen;

(13) Any material, compound, mixture or preparation containing not more than 50 milligrams of pentazocine or any of its salts plus naloxone HCl USP 0.5 milligrams, per dosage unit;

(14) Ketamine;

(15) Thiopental.

(d) Nalorphine.

(d.5) Buprenorphine.

(e) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, as set forth below:

(1) not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;

(2) not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized therapeutic amounts;

(3) (blank);

(4) (blank);

(5) not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts;

(6) not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts;

(7) not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts;

(8) not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with one or more active, non-narcotic ingredients in recognized therapeutic amounts.

(f) Anabolic steroids, except the following anabolic steroids that are exempt:

- (1) Androgyn L.A.;
- (2) Andro-Estro 90-4;
- (3) depANDROGYN;
- (4) DEPO-T.E.;
- (5) depTESTROGEN;
- (6) Duomone;
- (7) DURATESTRIN;
- (8) DUO-SPAN II;
- (9) Estratest;
- (10) Estratest H.S.;
- (11) PAN ESTRA TEST;
- (12) Premarin with Me;
- (13) TEST-ESTRO Cypic;
- (14) Testosterone Cyp;
- (15) Testosterone

1 injection; and

2 (16) Testosterone Enanthate-Estradiol Valerate
3 injection.

4 (g) Hallucinogenic substances.

5 (1) Dronabinol (synthetic) in sesame oil and
6 encapsulated in a soft gelatin capsule in a U.S. Food and
7 Drug Administration approved product. Some other names for
8 dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro-
9 6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d) pyran-1-ol) or
10 (-)-delta-9-(trans)-tetrahydrocannabinol.

11 (2) (Reserved).

12 (h) The Department may except by rule any compound,
13 mixture, or preparation containing any stimulant or depressant
14 substance listed in subsection (b) from the application of all
15 or any part of this Act if the compound, mixture, or
16 preparation contains one or more active medicinal ingredients
17 not having a stimulant or depressant effect on the central
18 nervous system, and if the admixtures are included therein in
19 combinations, quantity, proportion, or concentration that
20 vitiate the potential for misuse of the substances which have
21 a stimulant or depressant effect on the central nervous
22 system.

23 (i) Mitragynine.

24 (j) 7-hydroxymitragynine.

25 (Source: P.A. 103-881, eff. 1-1-25.)

1 (720 ILCS 642/Act rep.)

2 Section 10. The Kratom Control Act is repealed.